GlassScriptPhysician profile
Brian Yuan Chou
NPI 1386908556
$18,079.33
in general payments reported to CMS, 2019-2025
60 companies · $3,964 in 2025
The $3,964 reported for 2025 was more than what 86% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,824 · 2020: $930 · 2021: $764 · 2022: $5,431 · 2023: $887 · 2024: $1,279 · 2025: $3,964.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,957 · Consulting Fee: $2,130 · Education: $42.50.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,957.30 |
| Consulting Fee | $2,130.00 |
| Education | $42.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $5,640.74 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Azurity Pharmaceuticals, INC. | $4,242.69 | 2022 | |
| Medtronic Minimed, INC. | $1,543.04 | 2019 | |
| Sanofi-Aventis U.S. LLC | $951.60 | 2020-2025 | |
| Astrazeneca Pharmaceuticals LP | $711.30 | 2019-2023 | Farxiga |
| Bayer Healthcare Pharmaceuticals INC. | $688.87 | 2021-2025 | |
| Lilly USA, LLC | $542.98 | 2019-2025 | Jardiance, Mounjaro, Zepbound |
| Dexcom, INC. | $385.60 | 2019-2024 | Dexcom G6 Transmitter |
| Beta Bionics, INC. | $305.74 | 2023-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
| Abbvie INC. | $275.33 | 2019-2025 | Vraylar |
| Radius Health, INC. | $208.51 | 2019-2025 | Tymlos |
| Janssen Pharmaceuticals, INC | $187.42 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $126.52 | 2019-2024 | Jardiance, Synjardy |
| Corcept Therapeutics | $125.36 | 2024-2025 | Korlym |
| Insulet Corporation | $122.36 | 2020-2025 | Omnipod |
Show all 59 companies
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Chou listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.